Powderject Pharmaceuticals

Article Abstract:

Powderject Pharmaceuticals develops drug delivery systems, though it is unclear that the company's technology can make its technology commercial. A joint project with Boehringer and Roche has been cancelled, and the company faces competition from an increasing number of rivals. The company does, however, benefit from patents, and the technology is appropriate for some drugs, with powdered versions giving rise to better immune responses. Not all drugs can be used with this technology, especially since liquid based options are available.

Pharmaceutical Preparation Manufacturing, Pharmaceutical preparations, Drug Delivery Systems, Medical equipment and supplies industry, Medical equipment industry

---

Powderject

Article Abstract:

Powderject has developed a drug delivery device that is needle-free. The company is delaying its lead product's launch by two years and the chief designer has lost his job. The company's stock price has been affected. Credit Suisse First Boston and Raphael Zorn Hemsley both rate the company's stocks a buy, and Warburg Dillon Read rates them a strong buy. The company's stocks appear to be fairly priced, given the strong price rises for other stocks.

---

PowderJect Pharmaceuticals

Article Abstract:

PowderJect Pharmaceuticals's HIV diagnostic test could perform well, and the company is accumulating intellectual property from its research. There have been some project delays, and there is no certainty of the commercial viability of the company's device.

Similar abstracts:

• Abstracts: Shire Pharmaceuticals. Shire Pharmaceuticals: young at heart
• Abstracts: Precoat outshines market. Precoated growth. Adding colour
• Abstracts: Scottish and Southern Energy. Scottish Power

This website is not affiliated with document authors or copyright owners. This page is provided for informational purposes only. Unintentional errors are possible.